2026年3月期 第3四半期 決算説明会資料

This document is a presentation for JCR Pharmaceuticals Co., Ltd.'s financial results for the third quarter of the fiscal year ending March 2026. It details the company's performance overview, including revenue and operating profit trends, research and development expenditures, and the recognition of special profits. Revenue increased by 17.3% compared to the previous year, largely due to a significant rise in contract income. Operating profit showed improvement from the previous year, and special profits were also recorded. The document includes revised forecasts, highlighting expected sales growth from renal anemia and Fabry disease treatments. Overall, it outlines the company's growth strategy and market positioning.